Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy

Antiviral Therapy

Volumn 16, Issue 1, 2011, Pages 59-65

  Pulido, Federico ^a   Arribas, José R ^b   Hill, Andrew ^c   Van Delft, Yvon ^d   Moecklinghoff, Christiane ^e  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Janssen Cilag BV Netherlands   (Netherlands)

^e JANSSEN CILAG GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIREMIA; VIRUS MUTATION;

ADENINE; ADULT; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MOLECULAR TYPING; MUTATION; PHOSPHONIC ACIDS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 79951502126     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1710     Document Type: Article

References (22)

1. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of Adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
2. European AIDS Clinical Society. Guidelines: clinical management of HIV infected adults in Europe. Version 5-2. (Updated May 2010. Accessed 30 November 2010.) Available from http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 1-Treatment-of-HIV-Infected-Adults.pdf
3. Gupta R, Hill A, Sawyer A, Pillay D. Emergence of drug resistance in HIV type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
4. The UK Collaborative Group on HIV Drug Resistance, UK CHIC Study Group. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487-494.
5. Von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-1790. (Pubitemid 47403067)
6. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naive and experienced patients. HIV Clin Trials 2008; 9:418-427.
7. Dierynck I, De Meyer S, Lathouwers E, Vanden Abeele C, Lavreys L, de Bethune M. Characterisation of virologic failures in the randomized, controlled, Phase III ARTEMIS trial in treatment naive patients (week 96 analysis). 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 655.
8. Arribas JR, Horban A, Gerstoft J, et al. The MONET Trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010; 24:223-230.
9. Mitsuya Y, Winters M, Fessel J, et al. HIV-1 drug resistance genotype results in patients with plasma samples with HIV-1 RNA levels less than 75 copies/ml. J Acquir Immune Defic Syndr 2006; 43:56-59. (Pubitemid 44306488)
10. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2008; 47:266-285.
11. Stanford University HIV Drug Resistance Database. (Accessed May 2010.) Available from http://hivdb.stanford.edu/index.html
12. Lennox J, DeJesus E, Lazzarin A, et al. STARTMRK, a Phase III study of the safety and efficacy of raltegravir (RAL)-based versus efavirenz (EFV)-based combination therapy in treatment-naive HIV-infected patients. ICAAC/IDSA. 25-28 October 2008, Washington, DC, USA. Abstract H-896a.
13. Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine and efavirenz versus zidovudine, lamivudine and efavirenz for HIV. N Engl J Med 2006; 354:251-260. (Pubitemid 43113030)
14. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 23:279-91.
15. Pulido F, Arribas J, Delgado R, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
16. Delfraissy JF, Flandre P, Delaguerre C, et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 2008; 22:385-393.
17. Cameron DW, da Silva BA, Arribas JR, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198:234-240. (Pubitemid 352019289)
18. Hill A, Hirschel B, Katlama C. The Monark Trial: where now for boosted protease inhibitor monotherapy? AIDS 2008; 22:777-779. (Pubitemid 351450647)
19. Pulido F, Delgado R, Arranz A, et al. Three-year efficacy of lopinavir/ritonavir monotherapy in the OK04 Trial. 48th ICAAC. 25-28 October 2008, Washington DC, USA. Abstract H-12.
20. Wilkin TJ, McKinnon JE, DiRienzo AG, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. J Infect Dis 2009; 199:866-871.
21. Pulido F, Serrano O, Rivero A, et al. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY Study. 12th EACS Conference. 11-14 November 2009, Cologne, Germany. Oral presentation number PS4/6.
22. Katlama C, Valentin M, Algarte-Genin M, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomised open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010; 24:2365-2374.